Malaria – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Malaria – Pipeline Review, H2 2017’, provides an overview of the Malaria pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Malaria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Malaria and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Malaria

The report reviews pipeline therapeutics for Malaria by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Malaria therapeutics and enlists all their major and minor projects

The report assesses Malaria therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Malaria

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Malaria

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Malaria pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

AbbVie Inc

Actelion Pharmaceuticals Ltd

Agilvax Inc

Akshaya Bio Inc

Allergy Therapeutics Plc

Altimmune Inc

Amura Holdings Ltd

Artificial Cell Technologies Inc

AstraZeneca Plc

Bharat Biotech International Ltd

Cadila Healthcare Ltd

Carna Biosciences Inc

CEL-SCI Corp

Celgene Corp

Cilian AG

Daiichi Sankyo Co Ltd

DesignMedix Inc

Eisai Co Ltd

Expres2ion Biotechnologies ApS

Fosun International Ltd

GenVec Inc

Genzyme Corp

GeoVax Labs Inc

GlaxoSmithKline Plc

Hager Biosciences LLC

iBio Inc

Ichor Medical Systems Inc

Immunovaccine Inc

IPCA Laboratories Ltd

Jomaa Pharma GmbH

Kancera AB

Kymab Ltd

Lipocure Ltd

Lipotek Pty Ltd

LondonPharma Ltd

Marinomed Biotechnologie GmbH

Merck KGaA

MerLion Pharmaceuticals Pte Ltd

Microbiotix Inc

Mitsubishi Tanabe Pharma Corp

Mucosis BV (Inactive)

Mymetics Corp

Nobelpharma Co Ltd

Novartis AG

Osivax SAS

Otsuka Holdings Co Ltd

PaxVax Inc

Pfizer Inc

Protein Potential LLC

Rodos BioTarget GmbH

Sanaria Inc

Sanofi

SBI Pharmaceuticals Co Ltd

Selecta Biosciences Inc

Takeda Pharmaceutical Co Ltd

Theravectys SA

Titan Pharmaceuticals Inc

Toyama Chemical Co Ltd

VLP Biotech Inc

VLP Therapeutics LLC

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Malaria - Overview 6

Malaria - Therapeutics Development 7

Malaria - Therapeutics Assessment 31

Malaria - Companies Involved in Therapeutics Development 42

Malaria - Drug Profiles 69

Malaria - Dormant Projects 324

Malaria - Discontinued Products 332

Malaria - Product Development Milestones 334

Appendix 350

List of Tables

List of Tables

Number of Products under Development for Malaria, H2 2017 28

Number of Products under Development by Companies, H2 2017 30

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 31

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 32

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 33

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 34

Number of Products under Development by Universities/Institutes, H2 2017 35

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 37

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 38

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017 39

Products under Development by Companies, H2 2017 40

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 41

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 42

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 43

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 44

Products under Development by Companies, H2 2017 (Contd..5), H2 2017 45

Products under Development by Universities/Institutes, H2 2017 46

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 47

Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 48

Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017 49

Products under Development by Universities/Institutes, H2 2017 (Contd..4), H2 2017 50

Products under Development by Universities/Institutes, H2 2017 (Contd..5), H2 2017 51

Number of Products by Stage and Target, H2 2017 53

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 54

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 55

Number of Products by Stage and Mechanism of Action, H2 2017 57

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 58

Number of Products by Stage and Route of Administration, H2 2017 60

Number of Products by Stage and Molecule Type, H2 2017 62

Malaria – Pipeline by 4SC AG, H2 2017 63

Malaria – Pipeline by AbbVie Inc, H2 2017 64

Malaria – Pipeline by Actelion Pharmaceuticals Ltd, H2 2017 64

Malaria – Pipeline by Agilvax Inc, H2 2017 64

Malaria – Pipeline by Akshaya Bio Inc, H2 2017 65

Malaria – Pipeline by Allergy Therapeutics Plc, H2 2017 65

Malaria – Pipeline by Altimmune Inc, H2 2017 66

Malaria – Pipeline by Amura Holdings Ltd, H2 2017 66

Malaria – Pipeline by Artificial Cell Technologies Inc, H2 2017 66

Malaria – Pipeline by AstraZeneca Plc, H2 2017 67

Malaria – Pipeline by Bharat Biotech International Ltd, H2 2017 67

Malaria – Pipeline by Cadila Healthcare Ltd, H2 2017 68

Malaria – Pipeline by Carna Biosciences Inc, H2 2017 68

Malaria – Pipeline by CEL-SCI Corp, H2 2017 69

Malaria – Pipeline by Celgene Corp, H2 2017 69

Malaria – Pipeline by Cilian AG, H2 2017 70

Malaria – Pipeline by Daiichi Sankyo Co Ltd, H2 2017 70

Malaria – Pipeline by DesignMedix Inc, H2 2017 70

Malaria – Pipeline by Eisai Co Ltd, H2 2017 71

Malaria – Pipeline by Expres2ion Biotechnologies ApS, H2 2017 71

Malaria – Pipeline by Fosun International Ltd, H2 2017 72

Malaria – Pipeline by GenVec Inc, H2 2017 72

Malaria – Pipeline by Genzyme Corp, H2 2017 73

Malaria – Pipeline by GeoVax Labs Inc, H2 2017 73

Malaria – Pipeline by GlaxoSmithKline Plc, H2 2017 74

Malaria – Pipeline by Hager Biosciences LLC, H2 2017 74

Malaria – Pipeline by iBio Inc, H2 2017 75

Malaria – Pipeline by Ichor Medical Systems Inc, H2 2017 75

Malaria – Pipeline by Immunovaccine Inc, H2 2017 76

Malaria – Pipeline by IPCA Laboratories Ltd, H2 2017 76

Malaria – Pipeline by Jomaa Pharma GmbH, H2 2017 77

Malaria – Pipeline by Kancera AB, H2 2017 77

Malaria – Pipeline by Kymab Ltd, H2 2017 77

Malaria – Pipeline by Lipocure Ltd, H2 2017 78

Malaria – Pipeline by Lipotek Pty Ltd, H2 2017 78

Malaria – Pipeline by LondonPharma Ltd, H2 2017 79

Malaria – Pipeline by Marinomed Biotechnologie GmbH, H2 2017 79

Malaria – Pipeline by Merck KGaA, H2 2017 79

Malaria – Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2017 80

Malaria – Pipeline by Microbiotix Inc, H2 2017 80

Malaria – Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017 81

Malaria – Pipeline by Mucosis BV (Inactive), H2 2017 81

Malaria – Pipeline by Mymetics Corp, H2 2017 81

Malaria – Pipeline by Nobelpharma Co Ltd, H2 2017 82

Malaria – Pipeline by Novartis AG, H2 2017 82

Malaria – Pipeline by Osivax SAS, H2 2017 83

Malaria – Pipeline by Otsuka Holdings Co Ltd, H2 2017 83

Malaria – Pipeline by PaxVax Inc, H2 2017 84

Malaria – Pipeline by Pfizer Inc, H2 2017 84

Malaria – Pipeline by Protein Potential LLC, H2 2017 85

Malaria – Pipeline by Rodos BioTarget GmbH, H2 2017 85

Malaria – Pipeline by Sanaria Inc, H2 2017 85

Malaria – Pipeline by Sanofi, H2 2017 86

Malaria – Pipeline by SBI Pharmaceuticals Co Ltd, H2 2017 86

Malaria – Pipeline by Selecta Biosciences Inc, H2 2017 87

Malaria – Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 87

Malaria – Pipeline by Theravectys SA, H2 2017 88

Malaria – Pipeline by Titan Pharmaceuticals Inc, H2 2017 88

Malaria – Pipeline by Toyama Chemical Co Ltd, H2 2017 89

Malaria – Pipeline by VLP Biotech Inc, H2 2017 89

Malaria – Pipeline by VLP Therapeutics LLC, H2 2017 89

Malaria – Dormant Projects, H2 2017 345

Malaria – Dormant Projects, H2 2017 (Contd..1), H2 2017 346

Malaria – Dormant Projects, H2 2017 (Contd..2), H2 2017 347

Malaria – Dormant Projects, H2 2017 (Contd..3), H2 2017 348

Malaria – Dormant Projects, H2 2017 (Contd..4), H2 2017 349

Malaria – Dormant Projects, H2 2017 (Contd..5), H2 2017 350

Malaria – Dormant Projects, H2 2017 (Contd..6), H2 2017 351

Malaria – Dormant Projects, H2 2017 (Contd..7), H2 2017 352

Malaria – Discontinued Products, H2 2017 353

Malaria – Discontinued Products, H2 2017 (Contd..1), H2 2017 354

List of Figures

List of Figures

Number of Products under Development for Malaria, H2 2017 28

Number of Products under Development by Companies, H2 2017 29

Number of Products under Development by Universities/Institutes, H2 2017 35

Number of Products by Top 10 Targets, H2 2017 52

Number of Products by Stage and Top 10 Targets, H2 2017 52

Number of Products by Top 10 Mechanism of Actions, H2 2017 56

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 56

Number of Products by Top 10 Routes of Administration, H2 2017 59

Number of Products by Stage and Top 10 Routes of Administration, H2 2017 59

Number of Products by Top 10 Molecule Types, H2 2017 61

Number of Products by Stage and Top 10 Molecule Types, H2 2017 61

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports